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As bacteria continue to gain
resistance to a broader spectrum of
antibiotics, it is imperative that scientists
design and synthesize novel antibiotics
in order to combat the growing problem
with resistance. There are many different
ways to kill bacteria, one of them being
to prevent bacteria from synthesizing
proteins. Just like humans, all bacteria
have DNA that contains their genetic
information. This information is used by
the bacteria to make the proteins they
need to survive. The process of protein
synthesis, known as the Central Dogma
of Microbiology, involves transcription,
translation and translocation; each step
of this process has been the target of
different antibiotics.
Recently, the antibiotic Linezolid has
been proven effective in treating antibiotic
resistant bacteria such as methicillinresistant Staphylococcus aureus (MRSA),
multidrug-resistant Mycobacterium
tuberculosis (MDR-TB) and vancomycinresistant Enterococcus spp. (VRE).
Linezolid belongs to a class of antibiotics
known as Oxazolidinones, and it
prevents protein synthesis by stopping the
translation of mRNA into protein. This
translation process is mediated by the
bacterial ribosome, which is the target of
Linezolid. The bacterial ribosome is made
up of two subunits: the large (50s) subunit
and the small (30s) subunit. The bacterial
ribosome is distinctly different from that
of a humans allowing species specificity.
Linezolid binds to the peptidyltransferase
center (PTC) of the 50s ribosomal
subunit and halts protein synthesis.
Without the proteins necessary to regulate
processes within the cell, the bacteria
dies. Unfortunately, approximately 1 year
after its initial use, some bacteria have
presented with resistance to Linezolid.
The design and synthesis of
novel analogues of Linezolid with an
increased binding affinity may combat
bacterial resistance to Linezolid. The
structure of Linezolid bound to its
target indicates there was only one key
hydrogen bond between its morpholine
ring and a neighboring uracil group on
the ribosome. We hypothesize that we

can increase the binding affinity of our
analogues by increasing the number of
potential hydrogen bonding sites that
can interact with the key uracil group
or surrounding bases. The goal of this
project is to incorporate cyclic dipeptides
to introduce the necessary functionality.
The synthesis was designed to
utilize a core intermediate allowing for
functionalization at each end. Initially,
the construction of this core intermediate
was investigated. Several attempts
to form the key oxazolidinone were
performed; however, this process needs
to be optimized. A model system was
used to evaluate the coupling reaction
to attach the required cyclic dipeptide.
The coupling of glycine anhydride was
successful utilizing a copper (II) catalyst,
but this reaction needs to be optimized.
After investigating the oxazoldinone
ring formation and copper coupling
reactions, biological tests will be
performed in hopes that the novel
derivatives of Linezolid will present with
antibacterial activity. Further studies will
indicate whether these derivatives can be
used to treat drug resistant bacteria.
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